<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03866837</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR8900</org_study_id>
    <secondary_id>R01DK115449</secondary_id>
    <nct_id>NCT03866837</nct_id>
  </id_info>
  <brief_title>Prebiotic GOS and Lactoferrin With Iron Supplements</brief_title>
  <official_title>Prebiotic GOS and Lactoferrin for Beneficial Gut Microbiota With Iron Supplements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Federal Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jomo Kenyatta University of Agriculture and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ultimate goal of this research is to develop a means to safely administer iron
      supplements to infants in settings with a high infection burden. The investigators will
      conduct a randomized clinical trial in 6 month-old Kenyan infants in conjunction with
      mechanistic microbiota studies using a novel long-term continuous polyfermenter platform
      inoculated with immobilized fecal microbiota from Kenyan infants. Oral iron supplements are
      associated with a significant 15% increase in the rate of diarrhea in children in
      malaria-endemic areas. The most recent studies have shown that prebiotic
      galacto-oligosaccharides (GOS) can provide partial amelioration of the adverse effects of
      iron supplementation by enhancing the growth of barrier populations of bifidobacteria and
      lactobacilli. The investigators hypothesize that the combination of GOS with bovine
      lactoferrin, adding iron sequestration as well as antimicrobial and immunomodulatory
      activities, will provide almost complete protection against the adverse effects of added iron
      on the intestinal microbiota.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Iron deficiency, the principal cause of anemia globally, affects more than two billion
      individuals, predominantly infants, children and women of childbearing age. Iron deficiency
      impairs cognitive and behavioral development in childhood, compromises immune responsiveness,
      decreases physical performance, and when severe, increases mortality among infants, children
      and pregnant women. Effective prevention and treatment of iron deficiency uses iron
      supplements or fortificants to increase oral iron intake. Generally, only a small fraction of
      the added iron is absorbed in the upper small intestine, with 80% or more passing into the
      colon. Because iron is an essential micronutrient for growth, proliferation, and persistence
      for most intestinal microbes, the increase in iron availability has profound effects on the
      composition and metabolism of intestinal microbiota. In particular, iron is a prime
      determinant of colonization and virulence for most enteric gram-negative bacteria,
      includingmSalmonella, Shigella and pathogenic Escherichia coli. Commensal intestinal
      microorganisms, principally of the genera Bifidobacterium and Lactobacillus, require little
      or no iron, provide a barrier effect and can inhibit pathogen growth by a variety of methods,
      including sequestration of iron, competition for nutrients and for intestinal epithelial
      sites stabilization of intestinal barrier function, and production of antibacterial peptides
      and organic acids that lower the pH. Increases in unabsorbed iron can promote the growth of
      virulent enteropathogens that overwhelm barrier strains and disrupt the gut microbiota.

      We hypothesize that the combination of prebiotic GOS with bovine lactoferrin (bLF), adding
      iron sequestration, antimicrobial and immunomodulatory activities, will provide virtually
      complete protection against the adverse effects of added iron on the intestinal microbiota.
      Our research has two specific aims:

        1. to conduct a randomized, controlled double-blind 9-month clinical trial in 6-month old
           Kenyan infants comparing the effects on gut microbiome composition among groups
           receiving in-home fortification for 6 months with micronutrient powders containing 5 mg
           iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]) and (i)
           galacto-oligosaccharides (GOS; 7.5 g), (ii) bovine lactoferrin (bLF, 1.0 g), (iii) GOS
           (7.5 g) and bLF (1.0 g), and (iv) no GOS or bLF. Each infant will then be followed for
           an additional 3 months to determine the longer-term effects of the treatments.

        2. to examine mechanisms of iron, prebiotic GOS and iron-sequestering bLF on microbiota
           composition, enteropathogen development, microbiota functions and metabolic activity,
           and inflammatory potential in vitro with treatments paralleling those in Specific Aim 1,
           using immobilized fecal microbiota from Kenyan infants to inoculate our established
           long-term continuous polyfermenter intestinal model (PolyFermS) to mimic Kenyan infant
           colon conditions, together with cellular studies.

      Combining in vivo clinical and in vitro approaches will help guide formulation of safer iron
      supplements and fortificants and improve our understanding of the mechanisms whereby
      prebiotic GOS and iron-sequestering bLF support commensal microbiota to prevent iron-induced
      overgrowth by opportunistic enteropathogens.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>The study is a single-center, double-blinded, randomized, 9-month clinical trial with a 2X2 factorial design to determine the efficacy of galacto-oligosaccharides and bovine lactoferrin in preserving a beneficial gut microbiota during iron supplementation in Kenyan infants.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Stratified randomization will be carried out by the Trial Statistician using computer-generated randomly permuted blocks of size 2, 4 or 6 with stratification by gender and assignment of eligible infants to one of the 4 intervention groups using 4 color codes. Allocation will be known solely by the Trial Statistician and the Clinical Trial Safety Officer and concealed from all other study personnel.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of harmful to beneficial bacterial genera in fecal microbiota as determined by quantitative polymerase chain reaction (qPCR) at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>The primary outcome measure will be the ratio of the abundances of potentially harmful (enteropathogenic and/or enterotoxigenic E. coli, C. difficile, members of the C. perfringens group, B. cereus, S. aureus, sum of Shigella spp., and Salmonella) to beneficial (bifidobacteria and the group of Lactobacillus/Leuconostoc/Pediococcus spp.) bacterial genera in fecal microbiota as determined by quantitative polymerase chain reaction (qPCR) at 1 month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of harmful to beneficial bacterial genera in fecal microbiota as determined by quantitative polymerase chain reaction (qPCR) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>A key secondary outcome measure will be the ratio of the abundances of potentially harmful (enteropathogenic and/or enterotoxigenic E. coli, C. difficile, members of the C. perfringens group, B. cereus, S. aureus, sum of Shigella spp., and Salmonella) to beneficial (bifidobacteria and the group of Lactobacillus/Leuconostoc/Pediococcus spp.) bacterial genera in fecal microbiota as determined by quantitative polymerase chain reaction (qPCR) at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of harmful to beneficial bacterial genera in fecal microbiota as determined by quantitative polymerase chain reaction (qPCR) at 9 months</measure>
    <time_frame>9 months</time_frame>
    <description>A key secondary outcome measure will be the ratio of the abundances of potentially harmful (enteropathogenic and/or enterotoxigenic E. coli, C. difficile, members of the C. perfringens group, B. cereus, S. aureus, sum of Shigella spp., and Salmonella) to beneficial (bifidobacteria and the group of Lactobacillus/Leuconostoc/Pediococcus spp.) bacterial genera in fecal microbiota as determined by quantitative polymerase chain reaction (qPCR) at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota composition as determined by quantitative polymerase chain reaction (qPCR).</measure>
    <time_frame>1, 6 and 9 months</time_frame>
    <description>A secondary outcome measure will be the microbiota composition among study groups as determined by quantitative polymerase chain reaction (qPCR) measures of the abundances of potentially harmful (enteropathogenic and/or enterotoxigenic E. coli, C. difficile, members of the C. perfringens group, B. cereus, S. aureus, sum of Shigella spp., and Salmonella) and of beneficial (bifidobacteria and the group of Lactobacillus/Leuconostoc/Pediococcus spp.) bacterial genera at 1, 6, and 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhea</measure>
    <time_frame>1, 6 and 9 months</time_frame>
    <description>A secondary outcome measure will be the prevalence of diarrhea among study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malaria</measure>
    <time_frame>1, 6 and 9 months</time_frame>
    <description>A secondary outcome measure will be the prevalence of malaria among study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia</measure>
    <time_frame>1, 6 and 9 months</time_frame>
    <description>A secondary outcome measure will be the prevalence of anemia among study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron deficiency</measure>
    <time_frame>1, 6 and 9 months</time_frame>
    <description>A secondary outcome measure will be the prevalence of iron deficiency among study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron deficiency anemia</measure>
    <time_frame>1, 6 and 9 months</time_frame>
    <description>A secondary outcome measure will be the prevalence of iron deficiency anemia among study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>1, 6 and 9 months</time_frame>
    <description>A secondary outcome measure will be the prevalence of inflammation among study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory tract infections</measure>
    <time_frame>1, 6 and 9 months</time_frame>
    <description>A secondary outcome measure will be the prevalence of inflammation among study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other illnesses</measure>
    <time_frame>1, 6 and 9 months</time_frame>
    <description>A secondary outcome measure will be the prevalence of other illnesses among study groups</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Iron-deficiency</condition>
  <arm_group>
    <arm_group_label>Study group A: GOS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]) and galacto-oligosaccharides (GOS), 7.5 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group B: bLF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]), bovine lactoferrin (bLF), 1.0 g.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group C: GOS + bLF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]), galacto-oligosaccharides (GOS), 7.5 mg, and bovine lactoferrin (bLF), 1.0 g.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]) alone, with no galacto-oligosaccharides (GOS), and no bovine lactoferrin (bLF).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Galacto-oligosaccharides</intervention_name>
    <description>Galacto-oligosaccharides are classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, are components of cow's milk and have been used repeatedly in clinical trials without adverse effects.</description>
    <arm_group_label>Study group A: GOS</arm_group_label>
    <arm_group_label>Study group C: GOS + bLF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bovine lactoferrin</intervention_name>
    <description>Bovine lactoferrin is classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, is a component of cow's milk and has been used repeatedly in clinical trials without adverse effects.</description>
    <arm_group_label>Study group B: bLF</arm_group_label>
    <arm_group_label>Study group C: GOS + bLF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multiple micronutrient powders with 5 mg iron</intervention_name>
    <description>The multiple micronutrient powders are composed of Vitamin A, 400 μg; Vitamin D, 5 μg; Tocopherol Equivalents, 5 mg; Thiamine, 0.5 mg; Riboflavin, 0.5 mg; Vitamin B6, 0.5 mg; Folic Acid, 90 μg; Niacin, 6 mg; Vitamin B12, 0.9 μg; Vitamin C, 30 mg; Copper, 0.56 mg; Iodine, 90 μg; Selenium, 17 μg; Zinc, 4.1 mg; Phytase, 190 FTU; Iron, 5 mg [(as Ferrous fumarate, 2.5 mg and sodium iron ethylenediaminetetraacetate (NaFeEDTA), 2.5 mg].</description>
    <arm_group_label>Study group A: GOS</arm_group_label>
    <arm_group_label>Study group B: bLF</arm_group_label>
    <arm_group_label>Study group C: GOS + bLF</arm_group_label>
    <arm_group_label>Study group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  vaginal or cesarean delivery

          -  an infant age of 6 months (±3 weeks)

          -  mother ≥15 years of age

          -  infant still breastfeeding

          -  anticipated residence in the area for the study duration.

        Exclusion Criteria:

          -  inability to provide informed consent

          -  hemoglobin &lt; 70 g/L

          -  Z scores for weight-for-age (WAZ) or weight-for-height (WHZ) &lt;3,

          -  any maternal or infant chronic illness

          -  administration of any infant vitamin or mineral supplements for the past 2 months

          -  history of infant antibiotic treatment within 7 days before study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Weeks</minimum_age>
    <maximum_age>27 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary M Brittenham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary M Brittenham, MD</last_name>
    <phone>212 305 7005</phone>
    <email>gmb31@columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhezhen Jin</last_name>
    <phone>212 305 9404</phone>
    <email>zj7@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jomo Kenyatta University of Agriculture and Technology</name>
      <address>
        <city>Nairobi</city>
        <zip>00200</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon M Karanja, PhD</last_name>
      <phone>0675870001</phone>
      <email>Simon Karanja &lt;skaranja@jkuat.ac.ke&gt;</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swiss Federal Institute of Technology (ETH Zürich)</name>
      <address>
        <city>Zürich</city>
        <zip>8092</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael B Zimmermann, MD</last_name>
      <phone>+41 44 632 86 57</phone>
      <email>michael.zimmermann@hest.ethz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Verena Jäger</last_name>
      <phone>+41 44 632 84 21</phone>
      <email>verena.jaeger@hest.ethz.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Jaeggi T, Kortman GA, Moretti D, Chassard C, Holding P, Dostal A, Boekhorst J, Timmerman HM, Swinkels DW, Tjalsma H, Njenga J, Mwangi A, Kvalsvig J, Lacroix C, Zimmermann MB. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015 May;64(5):731-42. doi: 10.1136/gutjnl-2014-307720. Epub 2014 Aug 20.</citation>
    <PMID>25143342</PMID>
  </reference>
  <reference>
    <citation>Paganini D, Uyoga MA, Zimmermann MB. Iron Fortification of Foods for Infants and Children in Low-Income Countries: Effects on the Gut Microbiome, Gut Inflammation, and Diarrhea. Nutrients. 2016 Aug 12;8(8). pii: E494. doi: 10.3390/nu8080494. Review.</citation>
    <PMID>27529276</PMID>
  </reference>
  <reference>
    <citation>Zimmermann MB, Chassard C, Rohner F, N'goran EK, Nindjin C, Dostal A, Utzinger J, Ghattas H, Lacroix C, Hurrell RF. The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d'Ivoire. Am J Clin Nutr. 2010 Dec;92(6):1406-15. doi: 10.3945/ajcn.110.004564. Epub 2010 Oct 20.</citation>
    <PMID>20962160</PMID>
  </reference>
  <reference>
    <citation>Dostal A, Chassard C, Hilty FM, Zimmermann MB, Jaeggi T, Rossi S, Lacroix C. Iron depletion and repletion with ferrous sulfate or electrolytic iron modifies the composition and metabolic activity of the gut microbiota in rats. J Nutr. 2012 Feb;142(2):271-7. doi: 10.3945/jn.111.148643. Epub 2011 Dec 21.</citation>
    <PMID>22190022</PMID>
  </reference>
  <reference>
    <citation>Dostal A, Fehlbaum S, Chassard C, Zimmermann MB, Lacroix C. Low iron availability in continuous in vitro colonic fermentations induces strong dysbiosis of the child gut microbial consortium and a decrease in main metabolites. FEMS Microbiol Ecol. 2013 Jan;83(1):161-75. doi: 10.1111/j.1574-6941.2012.01461.x. Epub 2012 Aug 28.</citation>
    <PMID>22845175</PMID>
  </reference>
  <reference>
    <citation>Dostal A, Lacroix C, Pham VT, Zimmermann MB, Del'homme C, Bernalier-Donadille A, Chassard C. Iron supplementation promotes gut microbiota metabolic activity but not colitis markers in human gut microbiota-associated rats. Br J Nutr. 2014 Jun 28;111(12):2135-45. doi: 10.1017/S000711451400021X. Epub 2014 Feb 21.</citation>
    <PMID>24555487</PMID>
  </reference>
  <reference>
    <citation>Dostal A, Gagnon M, Chassard C, Zimmermann MB, O'Mahony L, Lacroix C. Salmonella adhesion, invasion and cellular immune responses are differentially affected by iron concentrations in a combined in vitro gut fermentation-cell model. PLoS One. 2014 Mar 27;9(3):e93549. doi: 10.1371/journal.pone.0093549. eCollection 2014.</citation>
    <PMID>24676135</PMID>
  </reference>
  <reference>
    <citation>Dostal A, Lacroix C, Bircher L, Pham VT, Follador R, Zimmermann MB, Chassard C. Iron Modulates Butyrate Production by a Child Gut Microbiota In Vitro. mBio. 2015 Nov 17;6(6):e01453-15. doi: 10.1128/mBio.01453-15.</citation>
    <PMID>26578675</PMID>
  </reference>
  <reference>
    <citation>Lacroix C, de Wouters T, Chassard C. Integrated multi-scale strategies to investigate nutritional compounds and their effect on the gut microbiota. Curr Opin Biotechnol. 2015 Apr;32:149-155. doi: 10.1016/j.copbio.2014.12.009. Epub 2015 Jan 3. Review.</citation>
    <PMID>25562815</PMID>
  </reference>
  <reference>
    <citation>Payne AN, Zihler A, Chassard C, Lacroix C. Advances and perspectives in in vitro human gut fermentation modeling. Trends Biotechnol. 2012 Jan;30(1):17-25. doi: 10.1016/j.tibtech.2011.06.011. Epub 2011 Jul 20. Review.</citation>
    <PMID>21764163</PMID>
  </reference>
  <reference>
    <citation>Payne AN, Chassard C, Banz Y, Lacroix C. The composition and metabolic activity of child gut microbiota demonstrate differential adaptation to varied nutrient loads in an in vitro model of colonic fermentation. FEMS Microbiol Ecol. 2012 Jun;80(3):608-23. doi: 10.1111/j.1574-6941.2012.01330.x. Epub 2012 Mar 27.</citation>
    <PMID>22324938</PMID>
  </reference>
  <reference>
    <citation>Tanner SA, Zihler Berner A, Rigozzi E, Grattepanche F, Chassard C, Lacroix C. In vitro continuous fermentation model (PolyFermS) of the swine proximal colon for simultaneous testing on the same gut microbiota. PLoS One. 2014 Apr 7;9(4):e94123. doi: 10.1371/journal.pone.0094123. eCollection 2014.</citation>
    <PMID>24709947</PMID>
  </reference>
  <reference>
    <citation>Zihler Berner A, Fuentes S, Dostal A, Payne AN, Vazquez Gutierrez P, Chassard C, Grattepanche F, de Vos WM, Lacroix C. Novel Polyfermentor intestinal model (PolyFermS) for controlled ecological studies: validation and effect of pH. PLoS One. 2013 Oct 30;8(10):e77772. doi: 10.1371/journal.pone.0077772. eCollection 2013.</citation>
    <PMID>24204958</PMID>
  </reference>
  <reference>
    <citation>Pasricha SR, Hayes E, Kalumba K, Biggs BA. Effect of daily iron supplementation on health in children aged 4-23 months: a systematic review and meta-analysis of randomised controlled trials. Lancet Glob Health. 2013 Aug;1(2):e77-e86. doi: 10.1016/S2214-109X(13)70046-9. Epub 2013 Jul 24. Review. Erratum in: Lancet Glob Health. 2014 Mar 2(3):e144.</citation>
    <PMID>25104162</PMID>
  </reference>
  <reference>
    <citation>Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, Regan M, Weatherall D, Chou DP, Eisele TP, Flaxman SR, Pullan RL, Brooker SJ, Murray CJ. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014 Jan 30;123(5):615-24. doi: 10.1182/blood-2013-06-508325. Epub 2013 Dec 2.</citation>
    <PMID>24297872</PMID>
  </reference>
  <reference>
    <citation>Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet. 2007 Aug 11;370(9586):511-20. Review.</citation>
    <PMID>17693180</PMID>
  </reference>
  <reference>
    <citation>Baumgartner J, Barth-Jaeggi T. Iron interventions in children from low-income and middle-income populations: benefits and risks. Curr Opin Clin Nutr Metab Care. 2015 May;18(3):289-94. doi: 10.1097/MCO.0000000000000168. Review.</citation>
    <PMID>25807351</PMID>
  </reference>
  <reference>
    <citation>Lönnerdal B. Bioactive Proteins in Human Milk: Health, Nutrition, and Implications for Infant Formulas. J Pediatr. 2016 Jun;173 Suppl:S4-9. doi: 10.1016/j.jpeds.2016.02.070. Review.</citation>
    <PMID>27234410</PMID>
  </reference>
  <reference>
    <citation>Manzoni P. Clinical Benefits of Lactoferrin for Infants and Children. J Pediatr. 2016 Jun;173 Suppl:S43-52. doi: 10.1016/j.jpeds.2016.02.075. Review.</citation>
    <PMID>27234411</PMID>
  </reference>
  <reference>
    <citation>Legrand D. Overview of Lactoferrin as a Natural Immune Modulator. J Pediatr. 2016 Jun;173 Suppl:S10-5. doi: 10.1016/j.jpeds.2016.02.071. Review.</citation>
    <PMID>27234406</PMID>
  </reference>
  <reference>
    <citation>Troesch B, Egli I, Zeder C, Hurrell RF, de Pee S, Zimmermann MB. Optimization of a phytase-containing micronutrient powder with low amounts of highly bioavailable iron for in-home fortification of complementary foods. Am J Clin Nutr. 2009 Feb;89(2):539-44. doi: 10.3945/ajcn.2008.27026. Epub 2008 Dec 23.</citation>
    <PMID>19106242</PMID>
  </reference>
  <reference>
    <citation>De-Regil LM, Suchdev PS, Vist GE, Walleser S, Peña-Rosas JP. Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age. Cochrane Database Syst Rev. 2011 Sep 7;(9):CD008959. doi: 10.1002/14651858.CD008959.pub2. Review. Update in: Cochrane Database Syst Rev. 2020 Feb 28;2:CD008959.</citation>
    <PMID>21901727</PMID>
  </reference>
  <reference>
    <citation>Rai D, Adelman AS, Zhuang W, Rai GP, Boettcher J, Lönnerdal B. Longitudinal changes in lactoferrin concentrations in human milk: a global systematic review. Crit Rev Food Sci Nutr. 2014;54(12):1539-47. doi: 10.1080/10408398.2011.642422. Review.</citation>
    <PMID>24580556</PMID>
  </reference>
  <reference>
    <citation>Liao Y, Jiang R, Lönnerdal B. Biochemical and molecular impacts of lactoferrin on small intestinal growth and development during early life. Biochem Cell Biol. 2012 Jun;90(3):476-84. doi: 10.1139/o11-075. Epub 2012 Feb 14. Review.</citation>
    <PMID>22332905</PMID>
  </reference>
  <reference>
    <citation>Ochoa TJ, Chea-Woo E, Baiocchi N, Pecho I, Campos M, Prada A, Valdiviezo G, Lluque A, Lai D, Cleary TG. Randomized double-blind controlled trial of bovine lactoferrin for prevention of diarrhea in children. J Pediatr. 2013 Feb;162(2):349-56. doi: 10.1016/j.jpeds.2012.07.043. Epub 2012 Aug 30.</citation>
    <PMID>22939927</PMID>
  </reference>
  <reference>
    <citation>Chen K, Chai L, Li H, Zhang Y, Xie HM, Shang J, Tian W, Yang P, Jiang AC. Effect of bovine lactoferrin from iron-fortified formulas on diarrhea and respiratory tract infections of weaned infants in a randomized controlled trial. Nutrition. 2016 Feb;32(2):222-7. doi: 10.1016/j.nut.2015.08.010. Epub 2015 Sep 3.</citation>
    <PMID>26602290</PMID>
  </reference>
  <reference>
    <citation>Chen EZ, Li H. A two-part mixed-effects model for analyzing longitudinal microbiome compositional data. Bioinformatics. 2016 Sep 1;32(17):2611-7. doi: 10.1093/bioinformatics/btw308. Epub 2016 May 14.</citation>
    <PMID>27187200</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Gary M Brittenham, MD</investigator_full_name>
    <investigator_title>Professor of Pediatrics and Medicine</investigator_title>
  </responsible_party>
  <keyword>Iron-deficiency</keyword>
  <keyword>Iron supplementation</keyword>
  <keyword>Galacto-oligosaccharides</keyword>
  <keyword>Lactoferrin</keyword>
  <keyword>Ferrous fumarate</keyword>
  <keyword>Clinical trial</keyword>
  <keyword>Microbiome</keyword>
  <keyword>PolyFermS</keyword>
  <keyword>Polyfermenter intestinal model</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trace Elements</mesh_term>
    <mesh_term>Lactoferrin</mesh_term>
    <mesh_term>Micronutrients</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

